Proliferative Diabetic Retinopathy
Conditions
Interventions
Three groups:Intravitreal injection of anti-VEGF drugs
Sponsors
The First Hospital of Qiqihar
Eligibility
Sex/Gender
All
Age
29 Years to 78 Years
Inclusion criteria
Inclusion criteria: Between Jan 2015 and Dec 2015, 53 patients of varying degrees of PDR in the First Hospital of Qiqihar were collected (60 eyes). There were 33 (55%) male and 27 (45%) female. The age was between 29-78 years old, with the average age of 58.83 (+/-3.62). Mean duration of DM was 26.57±5.82 years. All patients had a history of DM;Inclusion criteria: Between Jan 2015 and Dec 2015, 53 patients of varying degrees of PDR in the First Hospital of Qiqihar were collected (60 eyes). There were 33 (55%) male and 27 (45%) female. The age was between 29-78 years old, with the average age of 58.83 (+/-3.62). Mean duration of DM was 26.57±5.82 years. All patients had a history of DM;Inclusion criteria: Between Jan 2015 and Dec 2015, 53 patients of varying degrees of PDR in the First Hospital of Qiqihar were collected (60 eyes). There were 33 (55%) male and 27 (45%) female. The age was between 29-78 years old, with the average age of 58.83 (+/-3.62). Mean duration of DM was 26.57±5.82 years. All patients had a history of DM;Inclusion criteria: Between Jan 2015 and Dec 2015, 53 patients of varying degrees of PDR in the First Hospital of Qiqihar were collected (60 eyes). There were 33 (55%) male and 27 (45%) female. The age was between 29-78 years old, with the average age of 58.83 (+/-3.62). Mean duration of DM was 26.57±5.82 years. All patients had a history of DM;Inclusion criteria: Between Jan 2015 and Dec 2015, 53 patients of varying degrees of PDR in the First Hospital of Qiqihar were collected (60 eyes). There were 33 (55%) male and 27 (45%) female. The age was between 29-78 years old, with the average age of 58.83 (+/-3.62). Mean duration of DM was 26.57±5.82 years. All patients had a history of DM
Exclusion criteria
Exclusion criteria: Exclusion criteria included those who received prior intravitreal injection, underwent vitreous or retinal surgeries, and glaucoma. Patients with abnormal blood coagulation indexes and other diseases of surgical contraindication were also excluded.;Exclusion criteria: Exclusion criteria included those who received prior intravitreal injection, underwent vitreous or retinal surgeries, and glaucoma. Patients with abnormal blood coagulation indexes and other diseases of surgical contraindication were also excluded.;Exclusion criteria: Exclusion criteria included those who received prior intravitreal injection, underwent vitreous or retinal surgeries, and glaucoma. Patients with abnormal blood coagulation indexes and other diseases of surgical contraindication were also excluded.;Exclusion criteria: Exclusion criteria included those who received prior intravitreal injection, underwent vitreous or retinal surgeries, and glaucoma. Patients with abnormal blood coagulation indexes and other diseases of surgical contraindication were also excluded.;Exclusion criteria: Exclusion criteria included those who received prior intravitreal injection, underwent vitreous or retinal surgeries, and glaucoma. Patients with abnormal blood coagulation indexes and other diseases of surgical contraindication were also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCVA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time of operation;The incidence of iatrogenic retinal breaks;Use of the Intraocular coagulation;Use of Silicone filling;Vitreous clear time;The incidence of intraoperative and postoperative bleeding;intraocular pressure;Systemic complications and the incidence of systemic disease; | — |
Countries
China
Contacts
Public ContactWeikuan Gu, Hong Chen, Jinglin Cui;Weikuan Gu, Hong Chen, Jinglin Cui;Weikuan Gu, Hong Chen, Jinglin Cui;Weikuan Gu, Hong Chen, Jinglin Cui;Weikuan Gu, Hong Chen, Jinglin Cui ;;;;
;;;;
Outcome results
None listed